1012057-52-1

Basic information

• Product Name: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE
• Synonyms: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE;-7-methoxyquinazoline-4,6-diamine;N4-(3-Ethynylphenyl)
• CAS NO: 1012057-52-1
• Molecular Formula: C₁₇H₁₄N₄O
• Molecular Weight: 290.31926
• Mol File: 1012057-52-1.mol

Chemical Properties

• Boiling Point: 500.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.09±0.30(Predicted)
• CAS DataBase Reference: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE(1012057-52-1)
• EPA Substance Registry System: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE(1012057-52-1)

Safety Data

• Hazardous Substances Data: 1012057-52-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N4-(3-Ethynylphenyl)-7-methoxyquinazoline-4,6-diamine is used as a potential drug candidate for the treatment of various diseases, particularly cancer. Its anti-cancer properties have been observed in preclinical studies, where it has shown the ability to inhibit the growth of certain cancer cell lines.
Used in Cancer Research:
In cancer research, N4-(3-Ethynylphenyl)-7-methoxyquinazoline-4,6-diamine is utilized for investigating its mechanism of action and exploring its potential as a therapeutic agent. Further studies are required to understand its full therapeutic potential and to develop it into a viable treatment option for cancer patients.

Upstream product

• 54060-30-9 3-acetylenephenylamine 
• 207226-02-6 hydrochloric salt of m-aminophenylacetylene 
• 56602-33-6 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
• 55496-69-0 4-chloro-7-methoxy-6-nitroquinazoline 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 

Downstream Products

• 1203904-22-6 C₂₄H₁₈N₄O₃ 
• 1430203-46-5 (E)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide 

Relevant articles and documents

Tyrosine kinase inhibitor and pharmaceutical application thereof

The invention relates to a tyrosine kinase inhibitor containing a quinazoline derivative in the fields of tumor treatment medicines and the like, and application of the tyrosine kinase inhibitor in treatment medicines for inhibiting and treating diseases caused by overexpression of tyrosine kinase. The active ingredient of the tyrosine kinase inhibitor is a quinazoline derivative with a structure shown in the following formula: a functional group containing XCH2 (CH2) nC = O is introduced on the basis of a quinazoline structure, and the functional group is easily combined with cysteine sulfydryl through nucleophilic reaction to form a covalent bond so that the activity of tyrosine kinase is irreversibly inhibited.

Synthesis method and related intermediate of N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound

The present invention relates to a synthesis method and a related intermediate of a N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound.

Synthesis method and related intermediate of N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound

The present invention relates to a synthesis method and a related intermediate of a N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound.

Synthesis method and related intermediate of N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound

The present invention relates to a synthesis method and a related intermediate of a N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound.

QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR

The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo,

Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors

We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF

Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug ther

TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.

FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS

The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.